Literature DB >> 17949424

One-year follow-up of single-visit approach to cervical cancer prevention based on visual inspection with acetic acid wash and immediate cryotherapy in rural Thailand.

B Chumworathayi1, S Srisupundit, P Lumbiganon, K K Limpaphayom.   

Abstract

The aim is to evaluate 1) the visibility of cervical squamocolumnar junction (SCJ) after cryotherapy treatment and 2) to evaluate the effectiveness of cryotherapy treatment originally performed as part of a safety, acceptability, and feasibility (SAFE) demonstration project evaluating the SAFE of visual inspection with acetic acid (VIA) followed by immediate offer of cryotherapy among those who were tested positive and eligible for treatment. A total of 704 women presented at 1-year follow-up exam during which VIA was performed again by nurses. Six hundred and forty eight (92.0%) women received colposcopy and any kind of biopsy, if indicated, by trained physician colposcopists at a referral hospital. At 1 year, VIA nurses assessed 42 of 648 referred women (6.5%) as abnormal (test positive or suspected cancer). The SCJ was visible to the colposcopists in 91.7% (594/648) of the women. Among 42 women assessed as abnormal by the nurses, colposcopic findings were abnormal in 83.3% (35/42), with one low-grade squamous intraepithelial lesion, two high-grade squamous intraepithelial lesion (HSIL), and one adenocarcinoma confirmed later by biopsy. Among 606 VIA negative women, colposcopy was abnormal in only 23.4% (142/606), with two cases of HSIL confirmed later. Given that the SCJ was visible in the vast majority of women (91.7%) after cryotherapy, VIA could be used to provide follow-up for women previously treated. The disease negative rate after cryotherapy (no human papillomavirus infection, no cervical intraepithelial neoplasia, and no cancer) at 1 year after treatment was 85.5% (554/648).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17949424     DOI: 10.1111/j.1525-1438.2007.01112.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

1.  Perceptions of risk and barriers to cervical cancer screening at Moi Teaching and Referral Hospital (MTRH), Eldoret, Kenya.

Authors:  E Were; Z Nyaberi; N Buziba
Journal:  Afr Health Sci       Date:  2011-03       Impact factor: 0.927

2.  An Insight Into Cervical Cancer Screening and Treatment Capacity in Sub Saharan Africa.

Authors:  Jenell S Coleman; Michelle S Cespedes; Susan Cu-Uvin; Rose J Kosgei; May Maloba; Jean Anderson; Timothy Wilkin; Antoine Jaquet; Julia Bohlius; Kathryn Anastos; Kara Wools-Kaloustian
Journal:  J Low Genit Tract Dis       Date:  2016-01       Impact factor: 1.925

3.  Expanding the Single-Visit Approach for Cervical Cancer Prevention: Successes and Lessons From Burkina Faso.

Authors:  Yacouba Ouedraogo; Gahan Furlane; Timothee Fruhauf; Ousmane Badolo; Moumouni Bonkoungou; Tsigue Pleah; Jean Lankoande; Isabelle Bicaba; Eva S Bazant
Journal:  Glob Health Sci Pract       Date:  2018-06-29

4.  Cervical cancer screening: Safety, acceptability, and feasibility of a single-visit approach in Bulawayo, Zimbabwe.

Authors:  Muriel S Fallala; Robert Mash
Journal:  Afr J Prim Health Care Fam Med       Date:  2015-05-05

5.  Evaluating the implementation of cervical cancer screening programs in low-resource settings globally: a systematized review.

Authors:  J Andrew Dykens; Jennifer S Smith; Margaret Demment; E Marshall; Tina Schuh; Karen Peters; Tracy Irwin; Scott McIntosh; Angela Sy; Timothy Dye
Journal:  Cancer Causes Control       Date:  2020-03-17       Impact factor: 2.506

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.